Bayer Consensus Unlikely to Change Much After Earnings -- Market Talk

Dow Jones

Mar 05, 2025

0940 GMT - Bayer's fourth-quarter results beat sales and Ebitda expectations, Morgan Stanley analysts write. However, guidance came broadly in line, so limited changes to consensus estimates are expected, they add. By division, 2025 crop science and pharma guidance implies around 2% and 4% downside risk to divisional consensus Ebitda estimates, respectively, they say. There was limited updates on litigation, with Bayer confirming that it will file a petition for review with the U.S. Supreme Court on glyphosate claims. Meanwhile, a ruling from the Washington Supreme Court for the Erickson case--which relates to claims of personal injury related to alleged PCB exposure--is expected in the coming months. Shares rise 5.3%. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

March 05, 2025 04:40 ET (09:40 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2517999758"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2517999758\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2517999758?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-05 17:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517999758","market":"sg","top_or_hot":-1,"title":"Bayer Consensus Unlikely to Change Much After Earnings -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0940 GMT - Bayer's fourth-quarter results beat sales and Ebitda expectations, Morgan Stanley analysts write. However, guidance came broadly in line, so limited changes to consensus estimates are expected, they add. By division, 2025 crop science and pharma guidance implies around 2% and 4% downside risk to divisional consensus Ebitda estimates, respectively, they say. There was limited updates on litigation, with Bayer confirming that it will file a petition for review with the U.S. Supreme Court on glyphosate claims. Meanwhile, a ruling from the Washington Supreme Court for the Erickson case--which relates to claims of personal injury related to alleged PCB exposure--is expected in the coming months. Shares rise 5.3%. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 05, 2025 04:40 ET (09:40 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bayer Consensus Unlikely to Change Much After Earnings -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBayer Consensus Unlikely to Change Much After Earnings -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-05 17:40</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0940 GMT - Bayer's fourth-quarter results beat sales and Ebitda expectations, Morgan Stanley analysts write. However, guidance came broadly in line, so limited changes to consensus estimates are expected, they add. By division, 2025 crop science and pharma guidance implies around 2% and 4% downside risk to divisional consensus Ebitda estimates, respectively, they say. There was limited updates on litigation, with Bayer confirming that it will file a petition for review with the U.S. Supreme Court on glyphosate claims. Meanwhile, a ruling from the Washington Supreme Court for the Erickson case--which relates to claims of personal injury related to alleged PCB exposure--is expected in the coming months. Shares rise 5.3%. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 05, 2025 04:40 ET (09:40 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BAYRY","symbol_name":"Bayer A.G.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2517999758","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517999758","pubTimestamp":1741167600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0940 GMT - Bayer's fourth-quarter results beat sales and Ebitda expectations, Morgan Stanley analysts write. However, guidance came broadly in line, so limited changes to consensus estimates are expected, they add. By division, 2025 crop science and pharma guidance implies around 2% and 4% downside risk to divisional consensus Ebitda estimates, respectively, they say. There was limited updates on litigation, with Bayer confirming that it will file a petition for review with the U.S. Supreme Court on glyphosate claims. Meanwhile, a ruling from the Washington Supreme Court for the Erickson case--which relates to claims of personal injury related to alleged PCB exposure--is expected in the coming months. Shares rise 5.3%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BAYRY":"Bayer A.G."},"translate_title":"拜耳的共识在盈利后不太可能发生太大变化——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BAYRY":0.9},"content_text":"0940 GMT - Bayer's fourth-quarter results beat sales and Ebitda expectations, Morgan Stanley analysts write. However, guidance came broadly in line, so limited changes to consensus estimates are expected, they add. By division, 2025 crop science and pharma guidance implies around 2% and 4% downside risk to divisional consensus Ebitda estimates, respectively, they say. There was limited updates on litigation, with Bayer confirming that it will file a petition for review with the U.S. Supreme Court on glyphosate claims. Meanwhile, a ruling from the Washington Supreme Court for the Erickson case--which relates to claims of personal injury related to alleged PCB exposure--is expected in the coming months. Shares rise 5.3%. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 05, 2025 04:40 ET (09:40 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}